Literature DB >> 35450355

Identification of Slow-Binding Inhibitors of the BoNT/A Protease.

Ealin N Patel1, Lewis D Turner1,2, Mark S Hixon1, Kim D Janda1.   

Abstract

Botulinum neurotoxin A (BoNT/A) is a lethal toxin, which causes botulism, and is categorized as a bioterrorism threat, which causes flaccid paralysis and death. Botulinum A neurotoxicity is governed through its light chain (LC), a zinc metalloprotease. Pharmacological investigations aimed at negating BoNT/A's LC have typically looked to inhibitors that have been shown to inhibit the light chain's activity by reversible zinc chelation within its active site. This report outlines the first examples of nonpeptidic inhibitors of the BoNT/A LC that possess slow-binding kinetics, a needed logic to counteract the longevity of BoNT/A. Cyclopropane, alkyl, and alkenyl derivatives of 2,4-dichlorocinamic hydroxamic acid (DCHA) were shown to possess both one-step and two-step slow-binding kinetics. Structure-kinetic relationships (SKRs) were observed and were rationalized with the aid of docking models that predicted improved interactions with residues within a hydrophobic cleft adjacent to the active site.
© 2022 American Chemical Society.

Entities:  

Year:  2022        PMID: 35450355      PMCID: PMC9014515          DOI: 10.1021/acsmedchemlett.2c00028

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.632


  47 in total

1.  OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins.

Authors:  Edward Harder; Wolfgang Damm; Jon Maple; Chuanjie Wu; Mark Reboul; Jin Yu Xiang; Lingle Wang; Dmitry Lupyan; Markus K Dahlgren; Jennifer L Knight; Joseph W Kaus; David S Cerutti; Goran Krilov; William L Jorgensen; Robert Abel; Richard A Friesner
Journal:  J Chem Theory Comput       Date:  2015-12-01       Impact factor: 6.006

2.  Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry.

Authors:  Grant E Boldt; Jack P Kennedy; Kim D Janda
Journal:  Org Lett       Date:  2006-04-13       Impact factor: 6.005

3.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.

Authors:  Richard A Friesner; Robert B Murphy; Matthew P Repasky; Leah L Frye; Jeremy R Greenwood; Thomas A Halgren; Paul C Sanschagrin; Daniel T Mainz
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

4.  Validation of Matrix Metalloproteinase-9 (MMP-9) as a Novel Target for Treatment of Diabetic Foot Ulcers in Humans and Discovery of a Potent and Selective Small-Molecule MMP-9 Inhibitor That Accelerates Healing.

Authors:  Trung T Nguyen; Derong Ding; William R Wolter; Rocio L Pérez; Matthew M Champion; Kiran V Mahasenan; Dusan Hesek; Mijoon Lee; Valerie A Schroeder; Jeffrey I Jones; Elena Lastochkin; Margaret K Rose; Charles E Peterson; Mark A Suckow; Shahriar Mobashery; Mayland Chang
Journal:  J Med Chem       Date:  2018-09-27       Impact factor: 7.446

5.  The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety.

Authors:  Robert A Copeland
Journal:  Expert Opin Drug Discov       Date:  2010-04       Impact factor: 6.098

6.  Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A.

Authors:  Lucy Lin; Margaret E Olson; Takashi Sugane; Lewis D Turner; Margarita A Tararina; Alexander L Nielsen; Elbek K Kurbanov; Sabine Pellett; Eric A Johnson; Seth M Cohen; Karen N Allen; Kim D Janda
Journal:  J Med Chem       Date:  2020-09-18       Impact factor: 7.446

Review 7.  Mechanistic enzymology in drug discovery: a fresh perspective.

Authors:  Geoffrey A Holdgate; Thomas D Meek; Rachel L Grimley
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

8.  Enhancing the Pharmacokinetic Properties of Botulinum Neurotoxin Serotype A Protease Inhibitors Through Rational Design.

Authors:  Petr Capek; Yan Zhang; Deborah J Barlow; Karen L Houseknecht; Garry R Smith; Tobin J Dickerson
Journal:  ACS Chem Neurosci       Date:  2011-06-15       Impact factor: 4.418

9.  Novel Benzimidazole Inhibitors of Botulinum Neurotoxin/A Display Enzyme and Cell-Based Potency.

Authors:  Steven C Cardinale; Michelle M Butler; Gordon Ruthel; Jonathan E Nuss; Laura M Wanner; Bing Li; Ramdas Pai; Norton P Peet; Sina Bavari; Terry L Bowlin
Journal:  Botulinum J       Date:  2011

10.  Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain.

Authors:  Dejan Caglič; Michelle C Krutein; Kristin M Bompiani; Deborah J Barlow; Galit Benoni; Jeffrey C Pelletier; Allen B Reitz; Luke L Lairson; Karen L Houseknecht; Garry R Smith; Tobin J Dickerson
Journal:  J Med Chem       Date:  2014-01-15       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.